Holen Sie sich die Stockscreener-App
0.00
100.00%
-9.02
Schlusskurs vom Vortag:
$9.02
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$16.27
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Firmenname
Range Cancer Therapeutics Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
313.03 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
637.18 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
640.25 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
240.12 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
574.55 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf Aktie (CNCR) Neueste Nachrichten
4 Cancer Stocks to Consider in 2025 - The Motley Fool
When the Price of (CNCR) Talks, People Listen - news.stocktradersdaily.com
ICE to Expand NYSE Index Family With Launch of U.S. Tech Index and Broader Range of NYSE-Listed Indices - The Globe and Mail
The Best Biotech Stocks to Buy - Morningstar
When (CNCR) Moves Investors should Listen - news.stocktradersdaily.com
Robinhood Stock Sets Latest All-Time High on New Crypto Offerings - Investopedia
5 Small-cap Biotech ETFs to Watch - Investing News Network
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
(CNCR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor - Yahoo Finance
This ETF Could Turn $500 Per Month Into a $851,000 Portfolio Paying $30,000 in Annual Dividend Income - The Globe and Mail
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
Friday's big stock stories: What’s likely to move the market in the next trading session - CNBC
ETF Channel: Range Cancer Therapeutics ETF Implied Analyst Target Price $20.61, Upside 132.35% - AInvest
Trend Tracker for (CNCR) - news.stocktradersdaily.com
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
CIBC Asset Management launches three new actively managed CIBC ETFs, expanding its cash management and fixed income ETF suite - The Globe and Mail
Weekly ETF Industry Recap: U.S., Europe, and Canada HighlightsMay 5-10, 2025 - Trackinsight
Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF - The Joplin Globe
Learn to Evaluate (CNCR) using the Charts - news.stocktradersdaily.com
Cold Spring Harbor Laboratory’s Ludmila Pollock lauded as fellow of AAAS - TBR News Media
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Cathie Wood Bets on Nvidia, AMD Despite Chip Curbs and Dumps Microsoft Stock - The Globe and Mail
Long Term Trading Analysis for (CNCR) - news.stocktradersdaily.com
7 Best Pharmaceutical Stocks to Buy for Income | Investing - US News Money
From Panic to Positioning: Top ETFs to Watch After Asia’s Tariff Shock - The Globe and Mail
(CNCR) Investment Report - news.stocktradersdaily.com
10 Best Health Care Stocks to Buy for 2025 - US News Money
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Best Stocks Under $20 Right Now - Benzinga
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Nasdaq
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Nasdaq
QQQ ETF News, 3/19/2025 - The Globe and Mail
(CNCR) Proactive Strategies - Stock Traders Daily
Nasdaq Correction: Buy This Unstoppable ETF at a Discount - The Globe and Mail
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
VOO ETF News, 3/14/2025 - The Globe and Mail
Bull or Bear, These 2 ETFs Don’t Care - The Globe and Mail
VOO ETF News, 3/12/2025 - The Globe and Mail
Is the Fidelity High Dividend ETF the Smartest Investment You Can Make Today? - The Globe and Mail
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You? - The Globe and Mail
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? - The Globe and Mail
SCHD ETF News, 3/11/2025 - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
Why You Can Do Better Than the SPDR S&P 500 ETF Trust - The Globe and Mail
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Best Biotech Stocks to Buy in 2025 - The Motley Fool
(CNCR) Investment Analysis - news.stocktradersdaily.com
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Finanzdaten der Range Cancer Therapeutics Etf-Aktie (CNCR)
Es liegen keine Finanzdaten für Range Cancer Therapeutics Etf (CNCR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):